These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 5638562)
21. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. Alexanian R; Haut A; Khan AU; Lane M; McKelvey EM; Migliore PJ; Stuckey WJ; Wilson HE JAMA; 1969 Jun; 208(9):1680-5. PubMed ID: 5818682 [No Abstract] [Full Text] [Related]
24. [Myeloma : symptoms, diagnosis, treatment]. Piguet H; Borg JY; Monconduit M; Bizet M Rev Prat; 1979 Jan; 29(3):333-6, 339-44, 347-8. PubMed ID: 419356 [No Abstract] [Full Text] [Related]
25. Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein. Solomon A J Clin Invest; 1978 Jan; 61(1):97-108. PubMed ID: 618916 [TBL] [Abstract][Full Text] [Related]
26. [IgM myeloma]. Assaf ME; Pizzolato MA; De María HE; Gasparini S; Burucua JE Sangre (Barc); 1983; 28(5):642-7. PubMed ID: 6420914 [No Abstract] [Full Text] [Related]
27. Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. Pruzanski W; Watt JG Ann Intern Med; 1972 Dec; 77(6):853-60. PubMed ID: 4644164 [No Abstract] [Full Text] [Related]
28. Mollities et Fragilitas Ossium. Hoogstraten B J Kans Med Soc; 1981 Oct; 82(10):463-5, 470. PubMed ID: 7038005 [No Abstract] [Full Text] [Related]
29. Growth rates and responses to treatment in human myelomatosis. Hobbs JR Br J Haematol; 1969 Jun; 16(6):607-17. PubMed ID: 4184691 [No Abstract] [Full Text] [Related]
31. Plasma cell myeloma with D-myeloma protein (IgD myeloma). Fahey JL; Carbone PP; Rowe DS; Bachmann R Am J Med; 1968 Sep; 45(3):373-80. PubMed ID: 4175067 [No Abstract] [Full Text] [Related]
32. The incidence and possible relevance of Bence-Jones protein in the sera of patients with multiple myeloma. Sinclair D; Dagg JH; Smith JG; Stott DI Br J Haematol; 1986 Apr; 62(4):689-94. PubMed ID: 3964561 [TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients. Matzner Y; Benbassat J; Polliack A Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296 [No Abstract] [Full Text] [Related]
34. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)]. Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686 [No Abstract] [Full Text] [Related]
35. [Familial plasmocytoma in mother and son]. Klingler W; Daweke H Onkologie; 1985 Apr; 8(2):85-7. PubMed ID: 3889757 [TBL] [Abstract][Full Text] [Related]
36. Fragments of Bence-Jones proteins: products of degradation or of synthesis by plasmocytoma cells? Wetter O Klin Wochenschr; 1970 Apr; 48(8):482-4. PubMed ID: 5534829 [No Abstract] [Full Text] [Related]
37. [Clinical importance of paraprotein of the type kappa and lambda in Bence-Jones myeloma]. Iavorskiĭ LI; Andreeva NE; Antipova LG; Riauzova LN Probl Gematol Pereliv Krovi; 1979 Jun; 24(6):3-9. PubMed ID: 111238 [No Abstract] [Full Text] [Related]
38. Multiple myeloma. A clinical review. Rosen BJ Med Clin North Am; 1975 Mar; 59(2):375-86. PubMed ID: 1078867 [TBL] [Abstract][Full Text] [Related]